Guilherme Nader Marta· @GuiNaderMarta · X·· 1 day agoScore70
Body
FourLight-1 presented by @antgiorda at #ESMO26
Atirmociclib + fulvestrant improved median PFS vs investigator’s choice after CDK4/6i progression in HR+/HER2− metastatic breast cancer (9.4 vs 6.6 months; HR 0.60; p=0.0007)
@DFCI_BreastOnc @OncoAlert
104 views · 4 likes · 3 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgSource: Guilherme Nader Marta · x.com